GSK plc vs Tripadvisor Inc Common Stock — how do they compare? GSK plc trades at $50.41 (market cap $102.60B), while Tripadvisor Inc Common Stock trades at $10.63 (market cap $1.28B). The key difference: GSK plc is far larger — about 80.2× Tripadvisor Inc Common Stock's market cap, and GSK plc pays a 3.57% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| GSK | TRIP | |
|---|---|---|
Market Cap | $102.60B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $19.14 |
52-Week Low | $38.22 | $9.24 |
Enterprise Value | $123.04B | $1.33B |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Tripadvisor (TRIP) trades at $10.59, down 1.76% on the day, with a bearish technical signal and recent earnings misses. The company reported Q2 2026 EPS of $0.35, below the $0.42 estimate (Zacks Investment Research, 2026-08-06). Revenue was $1.89B in 2025, with net income improving to $40M. Analyst consensus is a $13.29 price target, but sentiment is mixed with 62.5% hold ratings. The sale of TheFork for $700M provides cash but highlights competitive pressures from AI travel tools.
The outlook is cautious; while valuation ratios like P/S of 0.72 appear attractive, weak profitability and competitive threats from AI-driven platforms pose significant risks. Near-term catalysts include TheFork sale proceeds and Viator's performance, but investor sentiment remains neutral amid earnings volatility and macro headwinds.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →